Anisodamine

Anisodamine

SCHEMBL27981908

CN1C2C[C@H](OC(=O)[C@@H](CO)c3ccccc3)CC1[C@@H](O)C2

nearest known ligand 0.72

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 4/20 0.72
CHRM2 P08172 3/20 0.72
CHRM5 P08912 3/20 0.72
CHRM3 P20309 3/20 0.72
CHRM4 P08173 3/20 0.72
KMT2A Q03164 3/20 0.72
LMNA P02545 3/20 0.72
HTR2C P28335 2/20 0.72
NFKB1 P19838 2/20 0.72
MEN1 O00255 2/20 0.72
BLM P54132 2/20 0.72
KDM4E B2RXH2 1/20 0.72
POLB P06746 1/20 0.72
ADRA2C P18825 1/20 0.72
ADRA1A P35348 1/20 0.72
HRH1 P35367 1/20 0.72
SLC22A1 O15245 1/20 0.72
ADRA1D P25100 1/20 0.72
TSHR P16473 2/20 0.68
CYP1A2 P05177 1/20 0.68

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Anisodamine SCHEMBL30317064 1.00 CHRM1 (0.72) CHRM1CHRM2CHRM5CHRM3CHRM4
Anisodamine SCHEMBL29353530 1.00 CHRM1 (0.72) CHRM1CHRM2CHRM5CHRM3CHRM4
Anisodamine SCHEMBL30679509 1.00 CHRM1 (0.72) CHRM1CHRM2CHRM5CHRM3CHRM4
Anisodamine SCHEMBL31098813 1.00 CHRM1 (0.72) CHRM1CHRM2CHRM5CHRM3CHRM4
Anisodamine SCHEMBL28725258 1.00 CHRM1 (0.72) CHRM1CHRM2CHRM5CHRM3CHRM4
Anisodamine SCHEMBL620576 1.00 CHRM1 (0.72) CHRM1CHRM2CHRM5CHRM3CHRM4
Anisodamine SCHEMBL30679510 1.00 CHRM1 (0.72) CHRM1CHRM2CHRM5CHRM3CHRM4
SCHEMBL16167837 0.84 CHRM1 (0.76) CHRM1CHRM2CHRM5CHRM3CHRM4
Atropine SCHEMBL8854381 0.84 CHRM1 (1.00) CHRM1CHRM2CHRM5CHRM3CHRM4
Atropine SCHEMBL41317 0.84 CHRM1 (1.00) CHRM1CHRM2CHRM5CHRM3CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260102359-A1 COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION ERESINA LLC (US) 2026-04-16 US disclosed
CN-114414679-B Method for detecting belladonna alkaloid in animal tissues 吉林省农业科学院 2024-05-07 CN disclosed
CN-117379367-A Ophthalmic pharmaceutical composition 艾尔健康眼药(辽宁)有限公司 2024-01-12 CN disclosed
CN-113662915-B Ophthalmic pharmaceutical composition 艾尔健康眼药(辽宁)有限公司 2023-11-28 CN disclosed
CN-113527286-B Method for separating and purifying anisodamine monomer from alkaloid extract 锦州拾正生物科技有限公司 2023-05-05 CN disclosed
CN-113440486-B An eye drop composition for preventing or treating ophthalmic diseases, and its preparation method 苏州欧康维视生物科技有限公司 2022-12-20 CN disclosed
CN-114414679-A Method for detecting belladonna alkaloid in animal tissue 吉林省农业科学院 2022-04-29 CN disclosed
CN-114276342-A Method for separating and purifying anisodamine monomer from plant extract 锦州拾正生物科技有限公司 2022-04-05 CN disclosed
CN-113662915-A Medicinal composition for eyes 艾尔健康医药(辽宁)有限公司 2021-11-19 CN disclosed
CN-113527286-A Method for separating and purifying anisodamine monomer from alkaloid leaching paste 锦州拾正生物科技有限公司 2021-10-22 CN disclosed
CN-113440486-A An eye drop composition for preventing or treating ophthalmic diseases, and its preparation method 苏州欧康维视生物科技有限公司 2021-09-28 CN disclosed
CN-111821259-A Medicinal composition for eyes 艾尔健康眼药(辽宁)有限公司 2020-10-27 CN disclosed
CN-105616893-A Compound preparation for preventing and improving trigeminal neuroma and preparation method thereof QING HUIBIN 2016-06-01 CN disclosed
CN-105194237-A Composition for treating lymphoma and preparation method of composition LI XIAO 2015-12-30 CN disclosed
CN-104707030-A Traditional Chinese medicine pills for treating esophageal cancer and preparation method thereof CAO YANXIN 2015-06-17 CN disclosed
CN-104547250-A Traditional Chinese medicine composition for inhibiting cancer cell proliferation and preparation method of traditional Chinese medicine composition GUO LIANGSU 2015-04-29 CN disclosed
CN-104208360-A Traditional Chinese medicine medicated bath for pruritus eczema and preparation method thereof JING YING 2014-12-17 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260102359-A1 COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION COL2A1, COLGALT1, PLOD3 CHRM1 1604/4885CHRM2 880/4885CHRM5 2064/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.